Express Scripts expanding PCSK9 coverage for FH patients

The Familial Hypercholesterolemia Foundation (Pasadena, Calif.) said it partnered with Express Scripts Holding Co. (NASDAQ:ESRX) to expand the PBM’s coverage of familial hypercholesterolemia patients, giving them broader access to PCSK9 inhibitors.

Under the PBM's new criteria, patients would qualify for prior authorization for a PCSK9 inhibitor if their LDL-C levels were at least 190 mg/dL when untreated, and were still higher than 70 mg/dL on maximally tolerated statins plus Zetia ezetimibe...